Your Good Partner in Biology Research

  1. 首页
  2. 试剂盒
  3. 酶联免疫试剂盒
  4. Human placenta growth factor,PLGF ELISA kit

Human placenta growth factor,PLGF ELISA kit

  • 中文名称：
    人胎盘生长因子(PLGF)酶联免疫试剂盒
  • 货号：
    CSB-E04707h
  • 规格：
    96T/48T
  • 价格：
    ￥3200/￥2500
  • 其他：

产品详情

  • 产品描述：

    This Human PGF ELISA Kit is suitable for qualitatively determining PGF concentrations in multiple biological fluids, including human serum, plasma, and tissue homogenates in vitro. PGF (PLGF) is a mitogen for endothelial cells and also acts as a pro-inflammatory cytokine. It has pro-angiogenic effects on the feto-placental circulation and supports trophoblast growth. Upon binding to VEGF- and neuropilin-receptor sub-types, PGF regulates a range of neural, glial, and vascular cell responses distinct from VEGF-A. PGF is an increasingly important molecule in the prediction, diagnosis, and treatment of pre-eclampsia. Increased PGF levels are detected in several inflammatory diseases and are involved in the recruitment and homing of regulatory immune cells. PGF is thus implicated in immune evasion mechanisms by inhibiting anti-tumor immunity within solid cancers.

    This kit uses the quantitative sandwich-based enzyme immunoassay technique to measure the amount of human PGF in the sample. Standards and samples are respectively added to the microplate wells pre-coated with an anti-human PGF antibody. Biotin-labeled PGF antibody, HRP-avidin, and TMB substrate are pipped into the microplate in turn. The capture antibody pre-coated on the plate captures the PGF in the rat samples. PGF binds to the biotinylated anti-human PGF monoclonal antibody. And the biotin on the biotinylated anti-human PGF monoclonal antibody binds to the avidin on the enzyme label, forming immune complexes. The color renders blue after the addition of the TMB substrate. The addition of the stop solution into the wells immediately turns the blue into yellow. The concentration of PGF in the samples is directly proportional to OD (450nm). Each manufactured lot of this ELISA kit was quality tested for criteria such as sensitivity, specificity, precision, linearity, and lot-to-lot consistency.

  • 别名：
    D12S1900 ELISA Kit; Pgf ELISA Kit; PGFL ELISA Kit; PIGF ELISA Kit; Placenta growth factor ELISA Kit; Placental growth factor ELISA Kit; Placental growth factor; vascular endothelial growth factor related protein ELISA Kit; PlGF 2 ELISA Kit; PlGF ELISA Kit; PLGF_HUMAN ELISA Kit; PlGF2 ELISA Kit; SHGC 10760 ELISA Kit
  • 缩写：
  • Uniprot No.：
  • 种属：
    Homo sapiens (Human)
  • 样本类型：
    serum, plasma, tissue homogenates
  • 检测范围：
    1.67 ng/mL-40 ng/mL
  • 灵敏度：
    0.7 ng/mL
  • 反应时间：
    1-5h
  • 样本体积：
    50-100ul
  • 检测波长：
    450 nm
  • 研究领域：
    Cancer
  • 测定原理：
    quantitative
  • 测定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<10%      
    Three samples of known concentration were tested twenty times on one plate to assess.  
    Inter-assay Precision (Precision between assays): CV%<15%      
    Three samples of known concentration were tested in twenty assays to assess.    
                 
  • 线性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human PLGF in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    　 Sample Serum(n=4)  
    1:1 Average % 90  
    Range % 85-96  
    1:2 Average % 90  
    Range % 83-97  
    1:4 Average % 95  
    Range % 90-100  
    1:8 Average % 96  
    Range % 89-101  
  • 回收率：
    The recovery of human PLGF spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range  
    Serum (n=5) 96 89-100  
    EDTA plasma (n=4) 95 91-101  
                 
                 
  • 标准曲线：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    ng/ml OD1 OD2 Average Corrected  
    40 2.004 1.986 1.995 1.948  
    20 1.316 1.345 1.331 1.284  
    10 0.759 0.817 0.788 0.741  
    3.3 0.353 0.352 0.353 0.306  
    1.67 0.207 0.219 0.213 0.166  
    0 0.046 0.048 0.047 　  
  • 数据处理：
  • 货期：
    3-5 working days

产品评价

靶点详情

  • 功能：
    Growth factor active in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. Isoform PlGF-2 binds NRP1/neuropilin-1 and NRP2/neuropilin-2 in a heparin-dependent manner. Also promotes cell tumor growth.
  • 基因功能参考文献：
    1. low serum level associated with stillbirth PMID: 28714317
    2. sFlt-1/PLGF was positively correlated with the severity of preterm preeclampsia. PMID: 30177039
    3. The relationship between PlGF and preeclampsia differed in women with obesity according to gestational diabetes status, which may suggest different mechanistic pathways to preeclampsia. PMID: 30177064
    4. A contingent strategy of measuring the sFlt-1/PlGF ratio at 24-28weeks in women previously selected by clinical factors and uterine artery Doppler enables an accurate prediction of preeclampsia/fetal growth restriction. PMID: 30177066
    5. modest correlation of serum-free PlGF-1 with placental volume and uterine artery Doppler pulsatility index PMID: 28714779
    6. PGF expression may have a role in lymphatic invasion, poorer response to chemotherapy and unfavorable prognosis of patients with serous epithelial ovarian cancer PMID: 29643276
    7. A single measurement of sFlt-1/PlGF ratio at third trimester to predict pre-eclampsia and intrauterine growth retardation occurring after 34weeks of pregnancy. PMID: 29674192
    8. The levels of sFlt-1, PlGF, and the sFlt-1/PlGF ratio in pre-eclamptic women with an onset at < 32 weeks were sig- ni fi cantly di ff erent from those in women with an onset at >/=32-33 weeks. PMID: 29674208
    9. In urban Mozambican women with symptoms and/or signs suggestive of preeclampsia, low maternal plasma PlGF concentrations are associated with increased risks of adverse pregnancy outcomes, especially early delivery and stillbirth. PMID: 29523269
    10. An sFlt-1:PlGF ratio above 655 is not predictive of impaired perinatal outcomes, and insufficiently reliable for predicting outcomes in cases with clinical signs of preeclampsia. PMID: 29523274
    11. The maternal sFlt-1 to PlGF ratio in women with hypertensive disorders in pregnancy carries prognostic value for the development of preeclampsia. PMID: 29523275
    12. Lower umbilical cord PlGF levels are associated with lower birth weight, deviating fetal growth patterns, and a higher odds of fetal growth retardation. PMID: 28926825
    13. Data suggest that circulating PGF levels fall by nearly one quarter during term labor (but not during elective caesarean section). PMID: 29277266
    14. The cross-talk between tumor-associated macrophages and NSCLC cells via PLGF/Flt-1 and TGFbeta receptor signaling may promote the growth and vascularization of NSCLC. PMID: 29991059
    15. PlGF level showed an inversely proportional effect on the foetal weight. PMID: 28326518
    16. Recombinant hPlGF-2 significantly improved contractile function and reduced LV end-systolic and end-diastolic volume indices with a concomitant increase in capillary and arteriolar density in ischemic myocardium, without aggravating atherosclerosis. PMID: 28397162
    17. these data suggest that PlGF may increase non-small cell lung cancer metastasis through SRp40-mediated mRNA splicing of VEGF. PMID: 28861767
    18. The present study investigated the interplay of VEGF-A165a isoform, the anti-angiogenic VEGF-A165b, placental growth factor (PIGF) and their receptors, VEGFR1 and VEGFR2, on junctional occupancy of VE-cadherin and macromolecular leakage in human endothelial monolayers and the perfused placental microvascular bed. PMID: 29054861
    19. PIGF enhances TLR-signaling upstream of IKK and contributes to an exaggerated pathologic pro-inflammatory state in response to activation of maternal and fetal mononuclear phagocytes by specific TLR agonists PMID: 28635072
    20. Lower PIGF and higher PAPP-A and free beta-hCG levels were found in the fetal circulation of near-term severe preeclamptic pregnancies PMID: 27809614
    21. The early variations of PIGF and soluble fms-like tyrosine kinase-1 concentrations in newly pregnant obstetric antiphospholipid syndrome (oAPS) may help to detect patients at low risk of placenta-mediated complications (PMC). PMID: 28126966
    22. There is a significant negative correlation between the concentration of sFLt-1 and PIGF in normal pregnancy. PMID: 26434493
    23. knockdown of PIGF in spheroid body cells derived from two gastric cancer cell lines reduced in vitro tumorigenicity and stemness properties of spheroid body cells such as self-renewal ability, colony forming, migratory, and MMPs activities and decreased ability to differentiation and angiogenesis PMID: 27735991
    24. Data showed that sFlt-1/PIGF ratio increases with volume overload and persistent hypoxia after surgery with CHD. PMID: 25388629
    25. Glioma cell-released PIGF can induce Bregs to suppress CD8(+) T cell activities. PMID: 25450457
    26. VEGF/PIGF levels were higher in neonates exposed to pre-eclampsia, and there was a significant negative correlation between birth weight and VEGF/PIGF levels. PMID: 25354293
    27. In chronic kidney patients not yet on dialysis, higher serum level of PIGF are associated with increased mortality, but not cardiovascular events. PMID: 25128974
    28. Soluble flt1 is increased in preeclampsia and is associated with decreased levels of bioactive PIGF. PMID: 24166749
    29. In high-risk patients the sFlt1/PIGF ratio can be used for an individual risk assessment with regard to PE, HELLP syndrome or IUGR. Serial measurements permit a risk-adapted prenatal care of these patients PMID: 24595913
    30. Gene expression revealed up-regulation of pro-angiogenic (PGF), anti-apoptotics (BAG-1, BCL-2), heart development (TNNT2, TNNC1) and extracellular matrix remodelling (MMP-2, MMP-7) genes in SM. PMID: 18805052
    31. In contrast to the effects of hypoxia on PIGF expression in other cells, hypoxia suppresses transcription of PIGF in trophoblasts. Regulation of PIGF transcription under hypoxic conditions is independent of HIF-1. PMID: 19712973
    32. Antibodies to PIGF may possibly be used as angiogenesis inhibitors. PMID: 18466718
    33. Human donor myocardium and biopsies from allografts without fibrin deposits express PIGF. PMID: 19201345
    34. anlalysis of levels of circulating PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus PMID: 17964973
    35. These data suggest that mechanical stretch of bronchial airway epithelial cells induces iNOS expression and induces PIGF release in an erk1/2 activation-dependent manner. PMID: 17028267
    36. Neither the hyperpermeability in response to simultaneous stimulation of VEGFR-1 and VEGFR-2 nor VEGFR-1-mediated severe inflammation was associated with VEGF-E(NZ7)/PIGF-induced angiogenesis. PMID: 16794222
    37. Overexpression of VEGF but not PIGF exacerbated the lipopolysaccharide-mediated toxic effects, supporting a pathophysiological role for VEGF in mediating the sepsis phenotype. PMID: 16702604
    38. Therapeutically administered human PIGF-1 demonstrates a desirable biological activity for promoting the growth of functionally relevant vasculature in mice. PMID: 16702473
    39. IL-17A, IL-17B, IL-17F and IL-23 in systemic lupus erythematosus patients were examined and the correlation between levels of the investigated cytokines and VEGF, PIGF, as well as number of endothelial cells, was investigated. PMID: 23661335
    40. Maternal serum sFlt-1 and PlGF are markedly decreased in threatened miscarriage patients. PMID: 21448460
    41. High PlGF and/or low sFlt-1/PlGF may be used to diagnose Peripartum Cardiomyopathy. PMID: 28552862
    42. In this context, our results demonstrate that D16F7 markedly inhibits chemotaxis and invasiveness of GBM cells and patient-derived GBM stem cells (GSCs) in response to VEGF-A and PlGF, suggesting that VEGFR-1 might represent a suitable target that deserves further investigation for GBM treatment. PMID: 28797294
    43. reduced in preeclampsia and fetal growth restriction PMID: 27865093
    44. Studied serum levels of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) as markers for early diagnosis of preeclampsia. PMID: 29267975
    45. A high sFlt-1/PlGF ratio was associated with adverse outcomes and a shorter duration to delivery in early-onset fetal growth restriction. PMID: 28737473
    46. HIV status had no effect on serum level PMID: 28627965
    47. low plasma levels at 19-25 and 26-31 weeks of gestation were independent risk factors for a small placenta at >/=35 weeks PMID: 28613009
    48. Data suggest that expression of PGF is down-regulated in placental trophoblasts from pregnancies complicated by fetal growth retardation compared with control placentas. PMID: 28676532
    49. placental expression not altered by placental dysfunction PMID: 28494189
    50. Report sensitivity of sFlt-1/PlGF ratio for diagnosis of preeclampsia and fetal growth restriction. PMID: 28501276

    显示更多

    收起更多

  • 亚细胞定位：
    Secreted. Note=The three isoforms are secreted but PlGF-2 appears to remain cell attached unless released by heparin.
  • 蛋白家族：
    PDGF/VEGF growth factor family
  • 组织特异性：
    While the three isoforms are present in most placental tissues, PlGF-2 is specific to early (8 week) placenta and only PlGF-1 is found in the colon and mammary carcinomas.
  • 数据库链接：

    HGNC: 8893

    OMIM: 601121

    KEGG: hsa:5228

    STRING: 9606.ENSP00000451040

    UniGene: Hs.252820